tradingkey.logo

Perrigo Q3 net sales miss estimates

ReutersNov 5, 2025 11:44 AM


Overview

  • Perrigo Q3 2025 net sales down 4.1%, missing analyst expectations

  • Adjusted EPS for Q3 2025 beats analyst estimates

  • Company updates FY 2025 outlook due to industry dynamics and market trends


Outlook

  • Perrigo revises 2025 outlook due to infant formula dynamics and soft OTC trends

  • Company expects 2025 adjusted EPS of $2.70 to $2.80, up 5% to 9%

  • Perrigo forecasts 2025 net sales growth of -2.5% to -3.0%


Result Drivers

  • OTC MARKET SHARE GAINS - Perrigo achieved dollar, unit, and volume share gains in five of seven OTC store brand categories despite soft market consumption trends

  • STRATEGIC BUSINESS REVIEWS - Ongoing strategic reviews of Infant Formula and Oral Care businesses, with a focus on portfolio evaluation

  • CURRENCY AND COST MANAGEMENT - Favorable currency translation and disciplined cost management partially offset declines in adjusted operating income


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Miss

$1.04 bln

$1.09 bln (3 Analysts)

Q3 Adjusted EPS

Beat

$0.80

$0.75 (3 Analysts)

Q3 EPS

$0.09

Q3 Adjusted Operating Income

Beat

$173 mln

$168.60 mln (3 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Perrigo Company PLC is $32.00, about 36.9% above its November 4 closing price of $20.19

  • The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nPn6XplXha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI